title: Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.
abstract: The purpose of this study was to analyze medical late effects among patients with chronic myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects included 248 CML survivors who received an HC transplant (related donors [RDs], n = 150; unrelated donors [URDs], n = 70; or autologous, n = 28) and had survived at least 2 years, and a comparison group of 317 siblings. Subjects completed a 238-item survey on medical late effects. Compared with siblings, survivors were at a higher risk of developing ocular, oral health, endocrine, gastrointestinal, musculoskeletal, neurosensory, and neuromotor impairments. Multivariate analysis limited to RD and URD recipients found that chronic graft-versus-host disease (cGVHD) was associated with a higher risk of hypothyroidism, osteoporosis, cardiopulmonary, neurosensory, and neuromotor impairments. Overall health was reported as excellent, very good, or good in 78% of subjects, although those with cGVHD were more likely to report poor overall health. URD survivors were more likely to report a need for assistance with routine activities and that their current health prevented work or school attendance. This study demonstrates that HCT survivors, regardless of donor type, have a high prevalence of long-term health-related complications. However, adverse medical late effects with significant morbidity were uncommon. Chronic GVHD is the most important predictor of adverse medical late effects and poor overall health.
authors.affiliation: University of Minnesota Cancer Center, Blood and Marrow Transplant Program, Department of Internal Medicine, University of Minnesota, Minneapolis, USA. baker084@umn.edu
authors.forename: K Scott
authors.initials: KS
authors.lastname: Baker
authors.forename: James G
authors.initials: JG
authors.lastname: Gurney
authors.forename: Kirsten K
authors.initials: KK
authors.lastname: Ness
authors.forename: Ravi
authors.initials: R
authors.lastname: Bhatia
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Liton
authors.initials: L
authors.lastname: Francisco
authors.forename: Philip B
authors.initials: PB
authors.lastname: McGlave
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Robison
authors.forename: David S
authors.initials: DS
authors.lastname: Snyder
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: Smita
authors.initials: S
authors.lastname: Bhatia
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D016022:Case-Control Studies; D002386:Cataract / Q000150:complications; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000150:complications; D006306:Health Surveys; D006801:Humans; D007037:Hypothyroidism / Q000150:complications; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000601:surgery*; D008297:Male; D009369:Neoplasms / Q000150:complications; D012008:Recurrence; D012306:Risk; D012650:Self Disclosure; D012727:Sex Characteristics; D035781:Siblings; D017741:Survivors; D013997:Time Factors; D014019:Tissue Donors; D014180:Transplantation; D016896:Treatment Outcome